Sandoz Lays Out Plan For Rebound With Top Line Stagnant In 2021
Core Operating Profit Falls By 12% As Reported; 14% In Constant Currencies
Novartis admits that its Sandoz division is not expected to enjoy turnover growth in 2022, due to a lack of material launches, but is planning for a rise in 2023 and beyond.
You may also be interested in...
Sandoz Says All Options Still Open After Spinoff Rumors
Sandoz has responded to recent rumors that parent company Novartis is favoring a spinoff of the generics and biosimilars business over a sale or retention, insisting that “all options remain open” as a strategic review of the unit continues.
Generics Industry Braces For New Wave Of Price Pressure
With pricing pressures already creeping up in recent years, 2022 is set to see the generics industry caught in the middle as prices are further squeezed while costs continue to rise. As major players prepare to announce their first-quarter financial results, In Vivo looks at views from industry leaders on how these pressures are affecting their businesses, and how they can be expected to play out.
Sandoz Does Not Budge On 2022 Expectations Despite Positive Start
A weak base for the prior year and several one-time items allowed Sandoz to post positive financial results for the first quarter of 2022, including a 26% jump in the company’s core operating profit. Electing not to upgrade its expectations for Sandoz this year, Novartis will continue to monitor the business amid an ongoing strategic review.